Skip to main content
Grafa
Health
TuHURA Biosciences Q2 cash drops to $1 million
Image for illustrative purposes only. Not a real photo.

TuHURA Biosciences Q2 cash drops to $1 million

Share
  • TuHURA Biosciences reported $1 million in cash at June 30, while Q2 R&D spending increased to $6.6 million.
  • HURA shares were unchanged at $2.30 in the latest available quote following the announcement.
  • The company says its $50 million credit facility should extend its cash runway into 2028 while supporting IFx-2.0, TBS-2025 and MDSC programs.

TuHURA Biosciences (NASDAQ:HURA) ended Q2 2026 with $1 million in cash as R&D spending rose to $6.6 million amid increased clinical activity.

R&D expense increased from $4.9 million a year earlier, while G&A expense rose to $2.1 million from $1.9 million.

TuHURA used $13 million in operating cash during the first half and generated $10.6 million from financing activities, including ATM sales and credit-facility draws.

Following the announcement, TuHURA Biosciences' share price was unchanged at $2.30 in the latest available quote.

TuHURA filed an IND for TBS-2025 in June and says it plans to begin a Phase 1b/2 trial in selected AML patients during the second half of 2026.

The company’s $50 million facility carries 12% annual interest and matures April 21, 2031, while TuHURA says it should provide funding into 2028.

Frequently asked questions